Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41200   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-003686-17
    Sponsor's Protocol Code Number:I4V-MC-JADY
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-06-26
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-003686-17
    A.3Full title of the trial
    A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
    Estudio fase 3, multicentrico para evaluar la seguridad y
    eficacia de Baricitinib en pacientes con artritis reumatoide
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 Study in Rheumatoid Arthritis
    Estudio fase 3 en artritis reumatoide
    A.3.2Name or abbreviated title of the trial where available
    RA-BEYOND
    A.4.1Sponsor's protocol code numberI4V-MC-JADY
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLilly S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEli Lilly and Company
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEli Lilly
    B.5.2Functional name of contact pointClinical Trial Registry Office
    B.5.3 Address:
    B.5.3.1Street AddressLilly Corporate Center, DC 1526
    B.5.3.2Town/ cityIndianapolis
    B.5.3.3Post code46285
    B.5.3.4CountryUnited States
    B.5.4Telephone number34916635354
    B.5.5Fax number34916633481
    B.5.6E-mailEU_Lilly_Clinical_Trials@lilly.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebaricitinib
    D.3.2Product code LY3009104
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNbaricitinib
    D.3.9.2Current sponsor codeLY3009104
    D.3.9.4EV Substance CodeSUB31583
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebaricitinib
    D.3.2Product code LY3009104
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNbaricitinib
    D.3.9.2Current sponsor codeLY3009104
    D.3.9.4EV Substance CodeSUB31583
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Rheumatoid arthritis
    Artritis Reumatoide
    E.1.1.1Medical condition in easily understood language
    Rheumatoid arthritis
    Artritis Reumatoide
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the long-term safety and tolerability of baricitinib.
    El objetivo principal del estudio es evaluar la seguridad y tolerabilidad a largo plazo de baricitinib
    E.2.2Secondary objectives of the trial
    To evaluate in patients initially randomized to receive baricitinib in the originating study, the effect of long-term administration of baricitinib on the progression of structural joint damage, joint space narrowing and bone erosion. score, duration of morning stiffness, and changes in the European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) scores and in healthcare resource utilization.
    Evaluar los pacientes que inicialmentes fueron aleatorizados con baricitinib en los estudios previos, los efectos a largo plazo de la administracion de baricitinib en la progresion del daño estructral de las articulaciones, estrechamiento de espacio articular y erosion osea, puntuacion de escalas, duracion de la rigidez matutina y cambio de las escalas de calidad de vida (EQ-5D-5L) y uso de recursos sanitarios
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Have completed the final active treatment study visit in Study I4V-MC-JADV, I4V-MC-JADZ, I4V-MC-JADX, JADW, or I4V-MC-JADA.
    Los pacientes se considerarán idóneos para ser incluidos en el estudio únicamente si cumplen el
    siguiente criterio:
    [1] Haber completado la visita final de tratamiento activo de los estudios JADV, JADZ, JADX, JADW o JADA.
    E.4Principal exclusion criteria
    Patients will be excluded from the study if they meet any of the following criteria:
    [2] have significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the patient if investigational product continues to be administered
    [3] have a known hypersensitivity to baricitinib or any component of this investigational product.
    [4] had investigational product permanently discontinued at any time during a previous baricitinib study
    [5] had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the patient?s participation in the study
    [6] have any other condition that, in the opinion of the investigator, renders the patient unable to understand the nature, scope, and possible consequences of the study or precludes the patient from following and completing the protocol
    [7] are females of childbearing potential who do not agree to use 2 forms of highly effective birth control when engaging in sexual intercourse while enrolled in the study and for at least 28 days following the last dose of investigational product
    [8] are males who do not agree to use 2 forms of highly effective birth control while engaging in sexual intercourse with female partners of childbearing potential while enrolled in the study and for at least 28 days following the last dose of investigational product
    [2] Presentar enfermedades significativas sin controlar (cerebrocardiovasculares ?por ejemplo, infarto de miocardio [IM], angina inestable, hipertensión arterial inestable, insuficiencia cardiaca grave o accidente cerebrovascular?, respiratorias, hepáticas, renales, gastrointestinales, endocrinas, hematológicas o trastornos neuropsiquiátricos) o valores analíticos anormales que se hayan presentado durante el estudio previo de baricitinib y que, en opinión del investigador, constituyan un riesgo inaceptable para el paciente en caso de que el producto en fase de investigación continúe administrándose.
    [3] Presentar hipersensibilidad conocida a baricitinib o a cualquier de los componentes de este producto en fase de investigación.
    [4] Haber sido retirado permanentemente del tratamiento con el producto en fase de investigación en cualquier momento del estudio previo de baricitinib.
    [5] Haber sido retirado temporalmente del tratamiento con el producto en fase de investigación en la visita final de un estudio previo de baricitinib y, en opinión del investigador, que ello constituya un riesgo inaceptable para el paciente en caso de que el paciente participe en el estudio.
    [6] Presentar cualquier otra enfermedad que, en opinión del investigador, impida al paciente entender la naturaleza, el alcance y las posibles consecuencias del estudio o le impida seguir y completar el protocolo.
    [7] Mujeres en edad fértil que no consientan en utilizar 2 métodos anticonceptivos muy eficaces cuando mantengan relaciones sexuales durante el estudio y al menos durante los 28 días posteriores a la administración de la última dosis del fármaco en fase de investigación.
    a. Se considera que una mujer no está en edad fértil si tiene ? 60 años
    de edad, o tiene ? 40 y < 60 años de edad y no ha tenido menstruaciones durante al menos 12 meses, o si es estéril de forma
    congénita o ha sido esterilizada quirúrgicamente (esto es, se ha
    sometido a histerectomía, ovariectomía bilateral o ligación de trompas).
    b. Los siguientes métodos anticonceptivos se consideran muy eficaces
    (la paciente deberá utilizar 2 de estos métodos con su pareja):
    Anticonceptivos orales, inyectables, implantados u hormonales (entre otros, píldoras anticonceptivas, implantes, parches transdérmicos, dispositivos hormonales vaginales o inyecciones de liberación prolongada).
    Preservativo con espermicida (espuma, gel, película vaginal, crema o supositorio).
    Métodos de barrera (diafragma o capuchón cervical) con un
    espermicida (espuma, gel, película vaginal, crema o supositorio).
    Dispositivo intrauterino.
    Sistema intrauterino (por ejemplo, espiral liberadora de
    progestina).
    En el caso de los varones, vasectomía (tras la vasectomía
    debe documentarse adecuadamente la ausencia de esperma
    en el semen).
    [8] Varones que no consientan en utilizar 2 métodos anticonceptivos muy eficaces (anteriormente descritos) cuando mantengan relaciones sexuales con mujeres en edad fértil, tanto durante el estudio como al menos durante los 28 días posteriores a la administración de la última dosis del fármaco en fase de investigación.
    E.5 End points
    E.5.1Primary end point(s)
    a) Proportion of patients experiencing Treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) over long term follow-up.
    b) Temporary study drug interruptions and/or permanent study drug discontinuations over the long term follow-up
    c) Vital signs and laboratory evaluations (including chemistry and hematology)
    a) Acontecimientos adversos surgidos durante el tratamiento (AAST), acontecimientos adversos de especial interés (AAEI) y acontecimientos adversos graves (AAG).
    b) Interrupciones temporales y permanentes de la administración del producto en fase de investigación.
    c) Constantes vitales y pruebas analíticas (entre otras, pruebas de bioquímica y hematología).
    E.5.1.1Timepoint(s) of evaluation of this end point
    a) All study visits.
    b) All study visits except Visits 2, 5b, 19, ET, and 801.
    c) All study visits.
    a) Todas las visitas del estudio
    b) Todas las visitas excepto visita 2, 5b, 19, ET and 801.
    c) All study visits.
    E.5.2Secondary end point(s)
    a) Proportion of patients who maintain an improvement of 20, 50, or 70 percent, respectively, in the American College of Rheumatology criteria (ACR20, ACR50 and ACR70)
    b) Proportion of patients who maintain a
    ? Disease Activity Score modified to include the 28 diathrodial joint count (DAS28)-high sensitivity C-reactive protein (hsCRP)/DAS28 erythrocyte sedimentation rate (ESR)?3.2,
    ? Clinical Disease Activity Index (CDAI) ?10, and
    ? Health Assessment Questionnaire Disability Index (HAQ-DI) improvement ?0.22 and ?0.3
    c)Structural joint damage as measured by modified Total Sharp Score (mTSS) [van der Heijde method])
    d) Proportion of patients with mTSS change ?0
    e) Joint space narrowing and bone erosion score
    f) Duration of morning stiffness
    g) European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) scores and healthcare resource utilization
    a) La proporción de pacientes que mantengan una mejoría del 20, 50 o 70 por ciento, respectivamente, de acuerdo con los criterios del Colegio Americano de Reumatología (ACR20, ACR50 y ACR70), desde el mes 6 (del estudio original) hasta los meses 12, 24, 36, 48 y 54 de tratamiento con baricitinib.
    b) La proporción de pacientes que mantengan una puntuación modificada de la actividad de la enfermedad para incluir el recuento de las 28 articulaciones diartrodiales (DAS28) - proteína C reactiva de alta
    sensibilidad (PCRas) / puntuación DAS28 - velocidad de sedimentación globular (VSG) ? 3,2 y un Índice de la Actividad de la Enfermedad Clínica (CDAI) ? 10, una mejoría en el Cuestionario de Evaluación de la Salud ? Índice de Discapacidad (HAQ-DI) ? 0,22 y ? 0,3 desde el mes 6 (del estudio original) hasta los meses 12, 24, 36, 48 y 54 del tratamiento con baricitinib.
    c) La variación desde el momento basal del estudio original hasta el mes 12 (estudio JADX), el mes 24 (estudios JADX, JADV y JADZ), el mes 36 (estudios JADA, JADV y JADZ) y el mes 48 (estudio JADA), en relación con el daño articular estructural, de acuerdo con la Puntuación Total de Sharp modificada (puntuación mTSS [método de van der Heijde]).
    d) La proporción de pacientes con una variación en la puntuación mTSS ? 0 en el período comprendido entre el momento basal del estudio original y el mes 12 (estudio JADX), el mes 24 (estudios JADX, JADV y JADZ), el mes 36 (estudios JADA, JADV y JADZ) y el mes 48 (estudio JADA).
    e) La variación desde el momento basal del estudio original hasta el mes 12 (estudio JADX), el mes 24 (estudios JADX, JADV y JADZ), el mes 36 (estudios JADA, JADV y JADZ) y el mes 48 (estudio JADA), en relación con el estrechamiento del espacio articular y la puntuación relativa a la erosión ósea.
    f) La variación observada en el período comprendido entre el momento basal del estudio original y los meses 12, 24, 36, 48 y 54 de tratamiento con baricitinib, en relación con la duración de la rigidez matutina.
    g) La variación observada desde el momento basal del estudio original hasta el mes 24, en relación con la puntuación del Cuestionario Europeo de Calidad de Vida ? 5 dimensiones, 5 niveles (EQ-5D-5L).
    E.5.2.1Timepoint(s) of evaluation of this end point
    a)Change from baseline to Month 6 of the originating study through Months 12, 24, 36, 48, and 54 of baricitinib treatment
    b)Same as a)
    c)Change from baseline of originating study to Month 12 (Study JADX), Month 24 (JADX, JADV and JADZ), Month 36 (JADA, JADV, and JADZ) and Month 48 (JADA)
    d)From baseline of originating study to Month 12 (Study JADX), Month 24 (JADX, JADV and JADZ), Month 36 (JADA, JADV, and JADZ) and Month 48 (JADA)
    e)Change from baseline of originating study to Month 12 (Study JADX), Month 24 (JADX, JADV and JADZ ), Month 36 (JADA, JADV and JADZ) and Month 48 (JADA)
    f)Change from baseline of originating study to 12, 24, 36, 48 and 54 months of baricitinib treatment
    g)Change from baseline of originating study through Month 24
    a,b) cambio desde el mes 6 hasta los meses 12, 24, 36, 48 y 54 de tratamiento con baricitinib.
    c) Cambio desde el momento basal del estudio original hasta el mes 12 (estudio JADX), el mes 24 (JADX, JADV y JADZ), el mes 36 ( JADA, JADV y JADZ) y el mes 48 (estudio JADA)
    d) período comprendido entre el momento basal del estudio original y el mes 12 ( JADX), el mes 24 ( JADX, JADV y JADZ), el mes 36 (JADA, JADV y JADZ) y el mes 48 (JADA).
    e)cambio desde el momento basal del estudio original hasta el mes 12 ( JADX), el mes 24 (JADX, JADV y JADZ), el mes 36 ( JADA, JADV y JADZ) y el mes 48 (estudio JADA)
    f)Cambio el inicio del estudio original y los meses 12, 24, 36, 48 y 54 de tratamiento baricitinib
    g) variación observada desde el momento basal del estudio original hasta el mes 24,
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA127
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Canada
    China
    Croatia
    Denmark
    Finland
    France
    Germany
    Greece
    Hungary
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Latvia
    Lithuania
    Mexico
    Netherlands
    Poland
    Portugal
    Romania
    Russian Federation
    Slovakia
    Slovenia
    South Africa
    Spain
    Sweden
    Switzerland
    Taiwan
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    the date of the last visit or last scheduled procedure shown in the study schedule for the last active patient in the study
    Fecha de la última visita o último procedimiento programado del estudio para el último paciente activo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 3000
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 350
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state36
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 636
    F.4.2.2In the whole clinical trial 3000
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Based upon longer term acceptability of the safety profile, the JADY study may be extended to allow for continued baricitinib treatment for up to 5 years.
    Deacuerdo con el perfil de seguridad el estudio JADY se puede extender a 5 años y permitir que los pacientes puedan beneficiarse del tratamiento hasta la comercializacion del farmaco.
    Si los pacientes no tubieran beneficio clinico seguiran con el tratamiento habitual para su enfermedad
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-07-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-06-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA